Publications
Detailed Information
Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2+metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sim, Sung Hoon | - |
dc.contributor.author | Park, In Hae | - |
dc.contributor.author | Jung, Kyung Hae | - |
dc.contributor.author | Kim, Sung-Bae | - |
dc.contributor.author | Ahn, Jin-Hee | - |
dc.contributor.author | Lee, Kyung-Hun | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Im, Young-Hyuck | - |
dc.contributor.author | Park, Yeon Hee | - |
dc.contributor.author | Sohn, Joohyuk | - |
dc.contributor.author | Kim, Yu Jung | - |
dc.contributor.author | Lee, Suee | - |
dc.contributor.author | Kim, Hee-Jun | - |
dc.contributor.author | Chae, Yee Soo | - |
dc.contributor.author | Park, Kyong Hwa | - |
dc.contributor.author | Nam, Byung-Ho | - |
dc.contributor.author | Lee, Keun Seok | - |
dc.contributor.author | Ro, Jungsil | - |
dc.date.accessioned | 2022-03-22T09:24:44Z | - |
dc.date.available | 2022-03-22T09:24:44Z | - |
dc.date.created | 2020-03-20 | - |
dc.date.created | 2020-03-20 | - |
dc.date.created | 2020-03-20 | - |
dc.date.issued | 2019-12 | - |
dc.identifier.citation | British Journal of Cancer, Vol.121 No.12, pp.985-990 | - |
dc.identifier.issn | 0007-0920 | - |
dc.identifier.other | 93023 | - |
dc.identifier.uri | https://hdl.handle.net/10371/177337 | - |
dc.description.abstract | BACKGROUND: The continuum of anti-HER2 agents is a standard treatment of HER2 + metastatic breast cancer (MBC). This study evaluated the efficacy of lapatinib plus vinorelbine in patients progressed on both trastuzumab and lapatinib treatments. METHODS: A total of 149 patients were randomly assigned to lapatinib with vinorelbine (LV) (n = 75; lapatinib, 1000 mg daily; vinorelbine 20 mg/m(2) D1, D8 q3w) or vinorelbine (V) (n = 74; 30 mg/m(2) D1, D8 q3w). The primary endpoint was progression-free survival (PFS) rate at 18 weeks. RESULTS: The median number of previous anti-HER2 therapies was 2 (range 2-5). There was no significant difference in PFS rate at 18 weeks between LV and V arms (45.9% vs 38.9%, p = 0.40). ORR was 19.7% in LV arm, and 16.9% in V arm (p = 0.88). PFS and OS did not differ between two arms (LV vs V; median PFS, 16 vs 12 weeks, HR = 0.86, 95% CI 0.61-1.22; median OS, 15.0 vs 18.9 months, HR = 1.07, 95% CI 0.72-1.58). Toxicity profiles were similar in both arms and all were manageable. CONCLUSIONS: Lapatinib plus vinorelbine treatment was tolerable; however, it failed to demonstrate the clinical benefits over vinorelbine alone in patients with HER2 + MBC after progression on both trastuzumab and lapatinib. | - |
dc.language | 영어 | - |
dc.publisher | Nature Publishing Group | - |
dc.title | Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2+metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16) | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1038/s41416-019-0618-z | - |
dc.citation.journaltitle | British Journal of Cancer | - |
dc.identifier.wosid | 000502070600001 | - |
dc.identifier.scopusid | 2-s2.0-85074795875 | - |
dc.citation.endpage | 990 | - |
dc.citation.number | 12 | - |
dc.citation.startpage | 985 | - |
dc.citation.volume | 121 | - |
dc.identifier.sci | 000502070600001 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | GROWTH-FACTOR RECEPTOR | - |
dc.subject.keywordPlus | PLUS CAPECITABINE | - |
dc.subject.keywordPlus | PROGRESSION | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.subject.keywordPlus | EMTANSINE | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.